Source-grounded facts extracted from Whitehawk Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Whitehawk Therapeutics, Inc. shareholders approved Ratification of BDO USA, P.C. as independent registered public accounting firm at the 2026-06-11 meeting.
“Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstentions 34,795,850 1,148,282 4,430,891”
Whitehawk Therapeutics, Inc. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.
“Proposal 2: To approve, on an advisory basis, the compensation of the named executive officers identified in the 2025 Summary Compensation Table in the “Executive Compensation” section of the Proxy Statement. For Against Abstentions Broker Non-Votes 22,896,061 6,013,600 3,623,688 7,841,674”
Whitehawk Therapeutics, Inc. shareholders approved Election of three Class III directors at the 2026-06-11 meeting.
“Behzad Aghazadeh, Ph.D. 26,666,124 5,867,225 7,841,674 Richard Maroun 27,701,332 4,832,017 7,841,674 Emma Reeve 27,704,564 4,828,785 7,841,674”
Whitehawk Therapeutics, Inc. entered into Securities Purchase Agreement with each of the purchasers named therein (the "PIPE Investors") valued at $87,500,000 (effective 2026-05-12).
“On May 12, 2026, Whitehawk Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers named therein (the “PIPE Investors”), pursuant to which the Company agreed to sell to the PIPE Investors (i) 4,330,866 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $3.92 per share, and (ii) 17,991,021 pre-funded warrants to acquire Common Stock (the “Pre-Funded Warrants”), at a purchase price of $3.9199 per Pre-Funded Warrant, for an aggregate purchase price of $87,500,000 (collectively, the “PIPE Financing”).”
Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was $22.2 million.
“Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights”
Whitehawk Therapeutics, Inc. reported the full-year ended December 31, 2025 results: net income $20.6 million.
“Net loss for the full-year ended December 31, 2025, was $20.6 million, as compared to $63.7 million for the same period in 2024.”
Whitehawk Therapeutics, Inc. reported the three months ended December 31, 2025 results: net income $23.3 million.
“Net loss for the three months ended December 31, 2025, was $23.3 million as compared to $18.3 million for the three months ended December 31, 2024.”
Whitehawk Therapeutics, Inc. completed a disposition involving KAKEN INVESTMENTS INC. for $102.4 million (closed 2025-03-25).
“and Aadi Subsidiary, Inc. on December 19, 2024. In accordance with the Purchase Agreement, upon the closing of the Divestiture, Purchaser paid to the Company a cash payment of $102.4 million (following applicable purchase price adjustments under the Purchase Agreement). The foregoing description of the Divestiture and the Purchase Agreement does not purport to be”
Whitehawk Therapeutics, Inc.: Board approved an amendment and restatement of the bylaws solely to reflect the name change to Whitehawk Therapeutics, Inc (effective 2025-03-18).
“Additionally, the Board approved an amendment and restatement of the Company’s bylaws solely to reflect the Name Change (the “ Amended and Restated Bylaws ”). The Amended and Restated Bylaws became effective upon the effectiveness of the Name Change Charter Amendment.”
Whitehawk Therapeutics, Inc.: Company amended its certificate of incorporation to change its name from Aadi Bioscience, Inc. to Whitehawk Therapeutics, Inc (effective 2025-03-18).
“The board of directors (the “ Board ”) of the Company approved an amendment to the Company’s amended and restated certificate of incorporation (the “ Charter ”), to change the Company’s name to Whitehawk Therapeutics, Inc. (the “ Name Change ”). On March 18, 2025, the Company filed a certificate of amendment (the “ Name Change Charter Amendment ”) to the Charter with the Secretary of State of the State of Delaware, which effected the Name Change.”
Neil Desai was terminated as Executive Chairman at Whitehawk Therapeutics, Inc..
“On August 20, 2024, Neil Desai, Ph.D, was notified that his employment as Executive Chairman of the Company will cease on October 1, 2024.”
Loretta Itri resigned as Chief Medical Officer at Whitehawk Therapeutics, Inc..
“On August 16, 2024, Loretta Itri, M.D. notified the board of directors of the Company (the “Board”) that her employment as Chief Medical Officer will cease effective October 1, 2024.”
Whitehawk Therapeutics, Inc. announced a restructuring with charges of approximately $2.2 to $2.5 million affecting workforce reduction (22 employees, representing approximately 32% of the Company’s workforce).
“a workforce reduction of 22 employees, representing approximately 32% of the Company’s workforce. The Company estimates that it will incur non-recurring charges of approximately $2.2 to $2.5 million in connection with the workforce reduction, primarily consisting of severance payments, employee benefits contributions and related costs. The Company expects that”
Whitehawk Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $5.4 million, net income $18.3 million.
“for the First Quarter 2024 and Provides Corporate Update Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES,”
Whitehawk Therapeutics, Inc. amended Amendment No.2 (the "Amendment") to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the "Agreement") with Fresenius Kabi, LLC (effective 2024-03-31).
“On April 1, 2024, Aadi Bioscience, Inc. (the “Company”) entered into Amendment No.2 (the “Amendment”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “Agreement”) with Fresenius Kabi, LLC (“Fresenius Kabi”). The Amendment is effective as of March 31, 2024.”
Whitehawk Therapeutics, Inc. reported Full year ended December 31, 2023 results: revenue $24.4 million, net income -$65.8 million.
“(EX-99.1) --- Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating”
Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2023 results: revenue $6.3 million, net income -$16.3 million.
“Total revenue for the quarter ended December 31, 2023, was $6.3 million, and $24.4 million for the full-year ended December 31, 2023, resulting from sales of FYARRO.”
Whitehawk Therapeutics, Inc. reported the quarter ended September 30, 2023 results: revenue $6.0 million, net income $16.3 million.
“total revenue resulting from sales of FYARRO for the quarter ended September 30, 2023, was $6.0 million”
Whitehawk Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 8, 2023, Aadi Bioscience, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended September 30, 2023.”
Scott Giacobello changed role as Chief Financial Officer at Whitehawk Therapeutics, Inc..
“Mr. Giacobello has served as the Company’s Interim CEO and President and principal executive officer since March 15, 2023, and will continue to serve as the Company’s Chief Financial Officer, a position he has held since November 2021, following Dr. Lennon’s appointment.”
David J. Lennon was appointed as Class II Director at Whitehawk Therapeutics, Inc..
“the Board increased the Board’s size from eight (8) to nine (9) directors and appointed Dr. Lennon to fill the resulting vacancy”
David J. Lennon was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..
“the Board of Directors (the “ Board ”) of Aadi Bioscience, Inc. (the “ Company ”) appointed David J. Lennon, Ph.D., to serve as the Company’s President and Chief Executive Officer and principal executive officer, effective as of October 2, 2023”
Whitehawk Therapeutics, Inc. reported the second quarter of 2023 results: revenue $6.2 million.
“Exhibit 99.1 Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and”
Whitehawk Therapeutics, Inc. shareholders approved Ratification of the appointment of BDO USA LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-14 meeting.
“For Against Abstentions 13,850,448 72,970 2,786”
Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory (non-binding) basis, the frequency of future Say-on-Pay Votes. at the 2023-06-14 meeting.
“1 Year 2 Years 3 Years Abstentions Broker Non-Votes 9,832,520 2,546 75,231 120,267 N/A”
Whitehawk Therapeutics, Inc. shareholders approved To approve, on an advisory basis, the compensation of the named executive officers identified in the 2022 Summary Compensation Table in the “Executive Compensation” section of the Proxy Statement. at the 2023-06-14 meeting.
“For Against Abstentions Broker Non-Votes 9,738,074 275,337 17,153 3,895,640”
Whitehawk Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors have been elected or qualified. at the 2023-06-14 meeting.
“Broker Director For Withheld Non-Votes Behzad Aghazadeh, Ph.D. 8,361,137 1,669,427 3,895,640 Richard Maroun 9,872,401 158,163 3,895,640 Emma Reeve 9,871,998 158,566 3,895,640”
Whitehawk Therapeutics, Inc. reported the quarter ended March 31, 2023 results: revenue $5.9 million, net income $15.2 million.
“Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients with appropriate”
Whitehawk Therapeutics, Inc. reported Fiscal year ended December 31, 2022 results: revenue $15.2 million, net income $60.5 million net loss.
“Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021. Net loss for the full-year 2022 ended December 31, 2022 was $60.5 million, as compared to $110.1 million for the period in 2021 (The prior year included the non-cash impairment charge of $74.2 million related to the acquired contract intangible asset incurred in conjunction with the Aerpio merger).”
Whitehawk Therapeutics, Inc. reported Three months ended December 31, 2022 results: revenue $5.2 million, net income $13.9 million net loss.
“Total revenue for the quarter ended December 31, 2022 was $5.2 million, and $15.2 million for the full-year ended December 31, 2022, resulting from sales of FYARRO. • Net loss for the three months ended December 31, 2022 was $13.9 million as compared to $16.0 million for the three months ended December 31, 2021.”
Mohammad Hirmand was appointed as Class II Director at Whitehawk Therapeutics, Inc..
“On March 24, 2023, Mohammad Hirmand, M.D. was appointed a Class II director by the Board of Directors (the “ Board ”) of the Company, effective March 27, 2023.”
Scott Giacobello was appointed as Interim Chief Executive Officer and President at Whitehawk Therapeutics, Inc..
“appointed Scott Giacobello as the Company’s Interim Chief Executive Officer and President, effective March 15, 2023.”
Scott Giacobello was appointed as Interim Chief Executive Officer and President at Whitehawk Therapeutics, Inc..
“Effective March 15, 2023, the Board appointed Scott Giacobello, the Company’s Chief Financial Officer, to serve as the Company’s Interim CEO and President and principal executive officer.”
Brendan Delaney resigned as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..
“On March 2, 2023, Brendan Delaney submitted a letter to the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”) resigning from his position as the Company’s President and Chief Executive Officer (“CEO”) and as a member of the Board of Directors, effective March 14, 2023.”
Whitehawk Therapeutics, Inc. amended Amendment No.1 with Fresenius Kabi, LLC (effective 2023-01-17).
“On January 17, 2023, Aadi Bioscience, Inc. (the “ Company ”) entered into Amendment No.1 (the “ Amendment ”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “ Agreement ”) with Fresenius Kabi, LLC (“ Fresenius Kabi ”).”
Whitehawk Therapeutics, Inc.: 董事会修订并重述了公司章程，以更新董事提名程序、股东会议程序并符合DGCL (effective 2022-12-06).
“On December 6, 2022, the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.”
Whitehawk Therapeutics, Inc. received a nasdaq compliance regained notice regarding audit committee (rules 5605(c)(2)(A)).
“November 23, 2022, Aadi Bioscience, Inc. (the “Company”) notified The Nasdaq Stock Market LLC (“Nasdaq”) of the Company’s non-compliance with Nasdaq’s audit committee composition requirements set forth in Nasdaq Listing Rule 5605(c)(2)(A), which require, among other things, an audit committee to consist of at least three members, each of whom is independent. The non-compliance was a result of Karin Hehenberger, M.D., Ph.D., a member of the Audit Committee (the “Audit Committee”) of the board of directors of the Company (the “Board”), not qualifying as independent pursuant to Nasdaq Listing Rul”
Whitehawk Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million, net income Net loss for the three months ended September 30, 2022 was $14.5 million.
“data in the first half of 2023. • Grew FYARRO net product sales . For the three months ended September 30, 2022, net product sales of FYARRO showed continued growth, ending with $4.2 million in sales in the third quarter, a 24% increase over the second quarter. • Leadership transition. Current CEO, Dr. Neil Desai, has been appointed Executive Chairman,”
Brendan Delaney was elected as Director at Whitehawk Therapeutics, Inc..
“the Board increased the Board’s size from seven (7) to eight (8) directors and elected Mr. Delaney to fill the resulting vacancy, effective as of the Effective Date.”
Brendan Delaney was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..
“and Brendan Delaney, Chief Operating Officer, to President and Chief Executive Officer of the Company, effective as of January 1, 2023”
Neil Desai was appointed as Executive Chairman at Whitehawk Therapeutics, Inc..
“the appointment of Neil Desai, founder, director, President and Chief Executive Officer of the Company, to Executive Chairman of the Company”
Lance Thibault departed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..
“Lance Thibault, who has served as the interim Chief Financial Officer since July 2021, will cease to be the interim Chief Financial Officer of the Company.”
Scott Giacobello was appointed as Chief Financial Officer and Treasurer at Whitehawk Therapeutics, Inc..
“appointed Scott Giacobello as its Chief Financial Officer and Treasurer, effective November 28, 2021”
Brendan Delaney was appointed as Chief Operating Officer at Whitehawk Therapeutics, Inc..
“On September 19, 2021, Aadi Bioscience, Inc. (the “ Company ”) appointed Brendan Delaney as the Company’s Chief Operating Officer, effective September 20, 2021”
Emma Reeve was appointed as Class III Director at Whitehawk Therapeutics, Inc..
“On September 8, 2021, Emma Reeve was appointed a Class III director by the Board.”
Lance Thibault was appointed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..
“Lance Thibault as the Company’s interim Chief Financial Officer.”
Neil Desai was appointed as President, Chief Executive Officer and Secretary at Whitehawk Therapeutics, Inc..
“the Board appointed Neil Desai, Ph.D., as the Company’s President, Chief Executive Officer and Secretary”
Regina Marek was terminated as Vice President, Principal Financial and Accounting Officer at Whitehawk Therapeutics, Inc..
“the Company terminated the employment of Joseph Gardner, Ph.D., the Company’s Principal Executive Officer, and Regina Marek, the Company’s Vice President, Principal Financial and Accounting Officer.”
Joseph Gardner was terminated as Principal Executive Officer at Whitehawk Therapeutics, Inc..
“the Company terminated the employment of Joseph Gardner, Ph.D., the Company’s Principal Executive Officer, and Regina Marek, the Company’s Vice President, Principal Financial and Accounting Officer.”
Cheryl Cohen resigned as Director at Whitehawk Therapeutics, Inc..
“Joseph Gardner, Ph.D., Steven Prelack, Pravin Dugel, M.D. and Cheryl Cohen resigned from the Board”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.